Yumei Li
Siwangting Road 180
Yangzhou, 225002, China
Yangzhou, 225002, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.
Journal: The Journal of dermatological treatment
Published: July 15, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
Journal: The Journal of dermatological treatment
Published: July 06, 2026
SSGJ-608 in moderate-to-severe plaque psoriasis: a multicenter, randomized, open-label, phase 3 study.
Journal: Frontiers in immunology
Published: February 13, 2026
A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: February 11, 2026
Efficacy and safety of topical GT20029 in male patients with androgenetic alopecia: a multicenter, randomized, double-blind, placebo-controlled phase 2 study.
Journal: The Journal of dermatological treatment
Published: December 02, 2025
Benzothiadiazole Ligand Modulation of Cu(I)-Based Coordination Polymers to Regulate Catalytic Properties for the Hydroboration of Alkynes.
Journal: Inorganic chemistry
Published: December 02, 2025
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: November 05, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.
Journal: International journal of dermatology
Published: September 24, 2025
Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial.
Journal: Advances in therapy
Published: September 04, 2025
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial.
Journal: The British journal of dermatology
Published: August 25, 2025
Association between sleep patterns, circadian rhythms, and hair loss in young adults.
Journal: Chronobiology international
Published: August 22, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 Trial.
Journal: Clinical and translational allergy
Published: July 24, 2025
Last Updated: 09/26/2026